| |
|
|
|
Keystone Symposia, Tahoe City, California
March 11 - 15, 2007
Tissue fibrosis or scarring is a leading cause of morbidity and mortality worldwide. Current health statistics suggest that almost 45% of all deaths in the western world are attributed to some type of chronic fibrotic disease. Fibrosis affects nearly all tissues and organ systems. Diseases in which fibrosis is a major cause of morbidity and mortality include the interstitial lung diseases, liver cirrhosis, kidney disease, heart disease, systemic sclerosis, among others. Fibrotic tissue remodeling can also influence cancer metastasis and accelerate chronic graft rejection in transplant recipients. Current treatments for fibrotic disorders target the inflammatory cascade, but they have been largely unsuccessful, primarily because the mechanisms that are involved in fibrogenesis are believed to be distinct from those involved in inflammation. Because mechanistic studies are difficult to carry out in humans, numerous experimental models have been developed over the past few years to dissect the immunological and molecular mechanisms of fibrosis. The first of new therapies based on these models is just beginning to approach clinical testing. The goal of this meeting is to bring together academic researchers, clinicians, and members of the pharmaceutical industry to discuss the most recent advances in the field and to identify common mechanistic themes of tissue fibrogenesis in various tissue systems. By bringing together a diverse group of researchers, the meeting will provide a more integrated perspective from basic disease mechanisms through to the more pragmatic challenges of clinical trial design in chronic progressive disease. Some of the topics that will be discussed include: extracellular matrix remodeling in fibrosis and cancer; the role of bone marrow in epithelial-mesenchymal transitions; experimental models of fibrosis; pulmonary, cardiac, liver, and kidney fibrosis; systemic sclerosis (scleroderma); as well as recent clinical developments with experimental anti-fibrotic drugs. This meeting will feature plenary talks from key investigators in the field and will also include workshops and poster sessions.
|
|
|
|
|
|
|
|
Organized by:
|
|
Thomas A. Wynn, W. Michael Gallatin and Mark Lupher, Jr. |
|
|
Invited Speakers:
|
|
- David Brenner, Columbia University Medical Center Presbyterian Hospital
- Barbara Burleigh, Harvard School of Public Health
- Lisa Coussens, University of California, San Francisco
- Jack Elias, Yale University
- Mark Entman, Baylor College of Medicine
- Scott Friedman, Mount Sinai School of Medicine
- Jack Gauldie, McMaster University
- Axel Gressner, Klinikum Rwth-Aachen
- Cory Hogaboam, University of Michigan Medical School
- Gary Hunninghake, University of Iowa College of Medicine
- Raghu Kalluri, Beth Israel Deaconess Medical Center
- David Liu, FibroGen, Inc.
- Eric Neilson, Vanderbilt University School of Medicine
- Sem Phan, University of Michigan Medical School
- Donald Rockey, University of Texas Southwestern Medical Center
- Dean Sheppard, University of California, San Francisco
- James Streisand, Genzyme Corporation
- Robert Strieter, University of California, Los Angeles
- John Varga, Northwestern University, Feinberg School of Medicine
- Thomas Wynn, National Institutes of Health
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
Nov. 13, 2006
|
|
|
|
|
|
|
|
Registration:
|
|
Please see website
|
|
|
E-mail:
|
|
info@keystonesymposia.org
|
|
|
|
|
|
|
|
|